Ginkgo Bioworks Holdings Inc SEC Filings

Insider transactions by Ginkgo Bioworks Holdings, Inc. (DNA): Chief Financial Officer Steven P. Coen reported vesting-related activity on August 21-22, 2025. Two sets of restricted stock units (RSUs) converted into Class A common shares: 587 RSUs and 156 RSUs were deemed acquired on August 21, 2025. A subsequent open-market sale on August 22, 2025 sold 310 shares at $12.396 each to satisfy tax withholding related to vesting. Following these transactions, the reporting person beneficially owned 11,112 and 4,847 Class A shares in the respective RSU pools, with total reported Class A holdings shown across lines. The Form 4 was signed by an attorney-in-fact on August 26, 2025.

Ginkgo Bioworks (DNA) narrowed its quarterly loss but continues to burn cash. Q2-25 revenue fell 12% YoY to $49.6 M as Biosecurity sales halved to $10.5 M, offset partly by 8% growth in higher-margin Cell Engineering to $39.1 M. Aggressive cost cuts—R&D down 60% to $53.4 M and G&A down 35% to $43.3 M—drove operating loss to $65.5 M versus $222.9 M last year. Net loss improved to $60.3 M (-$1.10 per diluted share) from $217.2 M (-$4.23).

Liquidity shifted from cash to securities. Cash & equivalents dropped 64% to $203.6 M, with $262.6 M deployed into marketable debt securities (now $270.1 M). Operating cash burn was $91.8 M versus $173.6 M a year ago. Total assets declined 11% to $1.23 B; equity fell to $613 M.

Restructuring and future obligations remain key risks. The 2024 restructuring—workforce cut >50% and facility consolidation—added $3.7 M this quarter and is expected to reach up to $29 M. A probable $24 M Google Cloud commitment shortfall looms in Aug-25, and non-refundable DNA supply payments to Twist total $11 M over 2026-27. Deferred revenue slipped 17% since year-end to $102.9 M, hinting at softer pipeline. Shares outstanding after the 1-for-40 reverse split stood at 55.4 M.

Ginkgo Bioworks Holdings, Inc. (DNA) filed a Form 144 disclosing a planned disposition of 2,200 Class A shares (estimated value $31,020) through Fidelity Brokerage beginning on 08/06/2025. The shares, acquired via restricted-stock vesting on 10/17/2022, equal roughly 0.005% of the reported 46.34 million shares outstanding—an immaterial portion of DNA’s float.

The account holder, Austin Che, has already sold small 99-share lots over the last three months, totaling 3,366 shares for about $27 k plus a 2,200-share block on 07/09/2025 for $24.6 k. Form 144 requires the filer to certify no possession of undisclosed material information and, if relying on Rule 10b5-1, that a compliant trading plan exists. No operational, earnings, or strategic data accompany the notice; it solely signals modest insider liquidity. Given the limited size, analysts should expect negligible impact on DNA’s share supply or valuation.

Ginkgo Bioworks Holdings, Inc. (DNA) has filed a Form 144 indicating a proposed sale of 2,200 Class A shares through Fidelity Brokerage Services, valued at $24,596, with an expected trade date of 07/09/2025 on the NYSE. The filing states that 46,344,630 shares are outstanding, meaning the contemplated sale represents roughly 0.005 % of the public float—well below the Rule 144 limit of 1 % or the average-daily-volume test.

The “Securities Sold During the Past 3 Months” table lists Austin Che as having executed 52 separate transactions of 99 shares each, totaling 5,148 shares between 04/09/2025 and 06/23/2025. No aggregate proceeds figure is supplied, but individual sales ranged from $567 to $941 per lot. The upcoming 2,200-share sale therefore continues a pattern of small, periodic dispositions.

No financial results, operational updates, or corporate events are disclosed in this notice. From a capital-markets perspective, the filing merely provides advance disclosure of a minor insider sale and does not alter the company’s fundamentals or capital structure.